Accounting policy.

No definition available.

Name:	fgen_AccountingPolicyLineItems
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of sales return.

+ References

No definition available.

+ Details

Name:	fgen_DescriptionOfSalesReturn
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	fgen_InitialUpfrontPayment
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum additional future option, clinical, regulatory, and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Profit share percent.

+ References

No definition available.

+ Details

Name:	fgen_ProfitSharePercent
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599

+ Details

Name:	us-gaap_NumberOfReportableSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Name:	us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Accounting Policies - Additional Information (Detail) shares in Millions		3 Months Ended		9 Months Ended
	Jun. 16, 2021 USD ($)	Sep. 30, 2021 shares	Sep. 30, 2020 shares	Sep. 30, 2021 Segment shares	Sep. 30, 2020 shares
Accounting Policy [Line Items]
Number of reportable segment \| Segment				1
Anti-dilutive shares outstanding \| shares		12.5	4.2	9.7	8.9
Description of payment term				The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.
Description of sales return				Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.
AstraZeneca Agreements [Member]
Accounting Policy [Line Items]
Profit share percent				50.00%
HiFiBiO Agreement [Member]
Accounting Policy [Line Items]
Initial upfront payment	$ 25,000,000.0
Maximum additional future option, clinical, regulatory, and commercial milestone payments	1,100,000,000
Contingent consideration	$ 0